IsoPSA: One Step Closer to a Better Prostate Cancer Blood Test
In 2017, a group of researchers from the Cleveland Clinic announced that they had developed a new molecular blood test that could tell the difference between prostate cancer and noncancerous conditions. It could even identify which patients had likely high-risk disease. This was based on a preliminary study conducted at five academic and community urology centers. An accurate blood test would mean that men with negative results would not need a biopsy! However, the preliminary results needed more confirmation.
A validation study was completed in time for the 2018 American Urological Association annual meeting in May. The news was just as good the second time around. The Cleveland team’s lead researcher, Dr. Eric Klein, commented on the results: